{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:45:55Z","timestamp":1792089955675,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00520-026-11238-0","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:20:55Z","timestamp":1790137255000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A phase 2 pharmacokinetic and pharmacodynamic dose-finding study of oral NEPA for chemotherapy-induced nausea and vomiting in pediatric patients with cancer"],"prefix":"10.1007","volume":"34","author":[{"given":"Priya","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Arakaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Melnikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliia","family":"Dementieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bernareggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingchao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulla","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Chaleff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"11238_CR1","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1056\/NEJMra1515442","volume":"374","author":"RM Navari","year":"2016","unstructured":"Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374:1356\u20131367. https:\/\/doi.org\/10.1056\/NEJMra1515442","journal-title":"N Engl J Med"},{"key":"11238_CR2","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1007\/s00520-012-1448-1","volume":"20","author":"P Fern\u00e1ndez-Ortega","year":"2012","unstructured":"Fern\u00e1ndez-Ortega P, Caloto MT, Chirveches E, Marquilles R, San Francisco J, Quesada A, Su\u00e1rez C, Zorrilla I, G\u00f3mez J, Zabaleta P, Nocea G, Llombart-Cussac A (2012) Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients\u2019 quality of life. Support Care Cancer 20:3141\u20133148. https:\/\/doi.org\/10.1007\/s00520-012-1448-1","journal-title":"Support Care Cancer"},{"issue":"11","key":"11238_CR3","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s00520-024-08939-9","volume":"32","author":"R Walker","year":"2024","unstructured":"Walker R, Dias S, Phillips RS (2024) Antiemetic medications for preventing chemotherapy-induced nausea and vomiting in children: a systematic review and Bayesian network meta-analysis. Support Care Cancer 32:747. https:\/\/doi.org\/10.1007\/s00520-024-08939-9","journal-title":"Support Care Cancer"},{"key":"11238_CR4","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1080\/14796694.2025.2479417","volume":"21","author":"YH Park","year":"2025","unstructured":"Park YH, Bianchini G, Cort\u00e9s J, Licata L, Vidal M, Iihara H, Roeland EJ, Jordan K, Scott\u00e9 F, Schwartzberg L, Navari RM, Aapro M, Rugo HS (2025) Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates. Future Oncol 21:1261\u20131272. https:\/\/doi.org\/10.1080\/14796694.2025.2479417","journal-title":"Future Oncol"},{"key":"11238_CR5","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1007\/s00520-010-1003-x","volume":"19","author":"SM Grunberg","year":"2011","unstructured":"Grunberg SM, Warr D, Gralla RJ, Rapoport BL, Hesketh PJ, Jordan K, Espersen BT (2011) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity\u2013state of the art. Support Care Cancer 19:S43\u2013S47. https:\/\/doi.org\/10.1007\/s00520-010-1003-x","journal-title":"Support Care Cancer"},{"key":"11238_CR6","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Lyman GH (2020) Antiemetics: ASCO guideline update. J Clin Oncol 38:2782\u20132797. https:\/\/doi.org\/10.1200\/JCO.20.01296","journal-title":"J Clin Oncol"},{"key":"11238_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102195","volume":"9","author":"J Herrstedt","year":"2024","unstructured":"Herrstedt J, Clark-Snow R, Ruhlmann CH, Molassiotis A, Olver I, Rapoport BL, Aapro M, Dennis K, Hesketh PJ, Navari RM, Schwartzberg L, Affronti ML, Garcia-Del-Barrio MA, Chan A, Celio L, Chow R, Fleury M, Gralla RJ, Giusti R, Jahn F, Iihara H, Maranzano E, Radhakrishnan V, Saito M, Sayegh P, Bosnjak S, Zhang L, Lee J, Ostwal V, Smit T, Zilic A, Jordan K, Scott\u00e9 F (2024) 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open 9:102195. https:\/\/doi.org\/10.1016\/j.esmoop.2023.102195","journal-title":"ESMO Open"},{"key":"11238_CR8","unstructured":"National Comprehensive Cancer Network (2025) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Antiemesis. Version 2.2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. Accessed 5 Jan 2026"},{"key":"11238_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30001","volume":"69","author":"P Patel","year":"2022","unstructured":"Patel P, Robinson PD, Cohen M, Devine K, Gibson P, Holdsworth MT, Neumann E, Orsey A, Phillips R, Spinelli D, Thackray J, van de Wetering M, Woods D, Cabral S, Sung L, Dupuis LL (2022) Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: a clinical practice guideline. Pediatr Blood Cancer 69:e30001. https:\/\/doi.org\/10.1002\/pbc.30001","journal-title":"Pediatr Blood Cancer"},{"key":"11238_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30883","volume":"71","author":"H Bloomhardt","year":"2024","unstructured":"Bloomhardt H, Rubin M, Xue Y, Jin Z, Masino L, Seidel D, Hijiya N, Beauchemin M (2024) Pediatric oncology provider perspectives and patient\/family perceptions of chemotherapy-induced nausea and vomiting management: experiences at an academic medical center. Pediatr Blood Cancer 71:e30883. https:\/\/doi.org\/10.1002\/pbc.30883","journal-title":"Pediatr Blood Cancer"},{"key":"11238_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31372","volume":"72","author":"RF Ben-Kenan","year":"2025","unstructured":"Ben-Kenan RF, Stafford LK, Temkit M, Brown J, Walsh A (2025) Vomiting despite adherence to guidelines: suboptimal control of vomiting in pediatric cancer patients. Pediatr Blood Cancer 72:e31372. https:\/\/doi.org\/10.1002\/pbc.31372","journal-title":"Pediatr Blood Cancer"},{"key":"11238_CR12","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S1470-2045(15)00520-3","volume":"17","author":"G Kov\u00e1cs","year":"2016","unstructured":"Kov\u00e1cs G, Wachtel AE, Basharova EV, Spinelli T, Nicolas P, Kabickova E (2016) Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study. Lancet Oncol 17:332\u2013344. https:\/\/doi.org\/10.1016\/S1470-2045(15)00520-3","journal-title":"Lancet Oncol"},{"key":"11238_CR13","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/MPH.0000000000001357","volume":"41","author":"NK Chaudhary","year":"2019","unstructured":"Chaudhary NK, John RR, Boddu D, Mahasampath G, Nesadeepam N, Mathew LG (2019) Palonosetron is a better choice compared with ondansetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in a resource-limited pediatric oncology center: results from a randomized control trial. J Pediatr Hematol Oncol 41:294\u2013297. https:\/\/doi.org\/10.1097\/MPH.0000000000001357","journal-title":"J Pediatr Hematol Oncol"},{"key":"11238_CR14","doi-asserted-by":"publisher","first-page":"806","DOI":"10.2174\/1568009622666220513094352","volume":"22","author":"M Aapro","year":"2022","unstructured":"Aapro M, Jordan K, Scott\u00e9 F, Celio L, Karthaus M, Roeland E (2022) Netupitant-palonosetron (NEPA) for preventing chemotherapy-induced nausea and vomiting: from clinical trials to daily practice. Curr Cancer Drug Targets 22:806\u2013824. https:\/\/doi.org\/10.2174\/1568009622666220513094352","journal-title":"Curr Cancer Drug Targets"},{"key":"11238_CR15","unstructured":"Akynzeo 300 mg\/0.5 mg hard capsules [summary of product characteristics] (2020) Helsinn Birex Pharmaceuticals Ltd"},{"key":"11238_CR16","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1093\/annonc\/mdu110","volume":"25","author":"PJ Hesketh","year":"2014","unstructured":"Hesketh PJ, Rossi G, Rizzi G, Palmas M, Alyasova A, Bondarenko I, Lisyanskaya A, Gralla RJ (2014) Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 25:1340\u20131346. https:\/\/doi.org\/10.1093\/annonc\/mdu110","journal-title":"Ann Oncol"},{"key":"11238_CR17","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1093\/annonc\/mdu096","volume":"25","author":"RJ Gralla","year":"2014","unstructured":"Gralla RJ, Bosnjak SM, Hontsa A, Balser C, Rizzi G, Rossi G, Borroni ME, Jordan K (2014) A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 25:1333\u20131339. https:\/\/doi.org\/10.1093\/annonc\/mdu096","journal-title":"Ann Oncol"},{"key":"11238_CR18","doi-asserted-by":"publisher","unstructured":"Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Lorusso V, Karthaus M, Schwartzberg L, Grunberg S (2014) A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25:1328\u20131333. https:\/\/doi.org\/10.1093\/annonc\/mdu101","DOI":"10.1093\/annonc\/mdu101"},{"key":"11238_CR19","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2165\/00003088-199937060-00004","volume":"37","author":"SN de Wildt","year":"1999","unstructured":"de Wildt SN, Kearns GL, Leeder JS, van den Anker JN (1999) Cytochrome P450 3A. Clin Pharmacokinet 37:485\u2013505. https:\/\/doi.org\/10.2165\/00003088-199937060-00004","journal-title":"Clin Pharmacokinet"},{"key":"11238_CR20","unstructured":"Aloxi (palonosetron HCl) injection for intravenous use [summary of product characteristics] (2018) Helsinn Birex Pharmaceuticals Ltd"},{"key":"11238_CR21","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.2217\/fon-2021-0023","volume":"17","author":"RM Navari","year":"2021","unstructured":"Navari RM, Binder G, Bonizzoni E, Clark-Snow R, Olivari S, Roeland EJ (2021) Single-dose netupitant\/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis. Future Oncol 17:3027\u20133035. https:\/\/doi.org\/10.2217\/fon-2021-0023","journal-title":"Future Oncol"},{"key":"11238_CR22","doi-asserted-by":"publisher","first-page":"15769","DOI":"10.1002\/cam4.6121","volume":"12","author":"L Zelek","year":"2023","unstructured":"Zelek L, Navari R, Aapro M, Scott\u00e9 F (2023) Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Cancer Med 12:15769\u201315776. https:\/\/doi.org\/10.1002\/cam4.6121","journal-title":"Cancer Med"},{"key":"11238_CR23","unstructured":"Emend (fosaprepitant) for injection, for intravenous use [prescribing information] (2022) Merck Sharp & Dohme LLC"},{"key":"11238_CR24","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s00520-019-4640-8","volume":"27","author":"S Baron-Hay","year":"2019","unstructured":"Baron-Hay S, Aapro M, Bernareggi A, Schwartzberg L (2019) Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer 27:1309\u20131317. https:\/\/doi.org\/10.1007\/s00520-019-4640-8","journal-title":"Support Care Cancer"},{"key":"11238_CR25","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1007\/s00520-019-4645-3","volume":"27","author":"G Badalamenti","year":"2019","unstructured":"Badalamenti G, Incorvaia L, Messina C, Musso E, Casarin A, Ricciardi MR, De Luca I, Bazan V, Russo A (2019) One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients. Support Care Cancer 27:3593\u20133597. https:\/\/doi.org\/10.1007\/s00520-019-4645-3","journal-title":"Support Care Cancer"},{"key":"11238_CR26","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/jcph.1338","volume":"59","author":"J Gilmore","year":"2019","unstructured":"Gilmore J, Bernareggi A (2019) Complementary pharmacokinetic profiles of netupitant and palonosetron support the rationale for their oral fixed combination for the prevention of chemotherapy-induced nausea and vomiting. J Clin Pharmacol 59:472\u2013487. https:\/\/doi.org\/10.1002\/jcph.1338","journal-title":"J Clin Pharmacol"},{"key":"11238_CR27","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1093\/jjco\/hyab079","volume":"51","author":"J Hara","year":"2021","unstructured":"Hara J, Kosaka Y, Koh K, Matsumoto K, Kumamoto T, Fujisaki H, Ishida Y, Suzuki R, Mochizuki S, Goto H, Yuza Y, Koga Y (2021) Phase III study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in pediatric patients. Jpn J Clin Oncol 51:1204\u20131211. https:\/\/doi.org\/10.1093\/jjco\/hyab079","journal-title":"Jpn J Clin Oncol"},{"key":"11238_CR28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/pr.2015.75","volume":"78","author":"FH Bloomfield","year":"2015","unstructured":"Bloomfield FH (2015) The challenges of research participation by children. Pediatr Res 78:109\u2013110. https:\/\/doi.org\/10.1038\/pr.2015.75","journal-title":"Pediatr Res"},{"key":"11238_CR29","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/wvn.12209","volume":"14","author":"S Crane","year":"2017","unstructured":"Crane S, Broome ME (2017) Understanding ethical issues of research participation from the perspective of participating children and adolescents: a systematic review. Worldviews Evid Based Nurs 14:200\u2013209. https:\/\/doi.org\/10.1111\/wvn.12209","journal-title":"Worldviews Evid Based Nurs"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11238-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11238-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11238-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:47:41Z","timestamp":1792086461000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11238-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["11238"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-11238-0","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with International Council for Harmonisation requirements and the Declaration of Helsinki. The study protocol was approved by the relevant independent ethics committees or institutional review boards.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For all patients, signed written informed consent by a parent\/legal guardian was obtained before study initiation in compliance with the local laws and regulations, as well as signed children\u2019s consent per local requirements.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"P. Patel: Nothing to declare. O. Arakaev: Nothing to declare. M. Melnikov: Nothing to declare. N. Dementieva: Nothing to declare. A. Bernareggi: Clinical Pharmacology Consultant, Italy. Nothing to declare. T. Chen: Employee of Helsinn Healthcare. T. Spinelli: Employee of Helsinn Healthcare. S. Chaleff: Nothing to declare.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1005"}}